Thymol-Induced Chemical Leukoderma Successfully Treated with 308-Nanometer Excimer Laser
- PMID: 32903934
- PMCID: PMC7445539
- DOI: 10.1159/000507899
Thymol-Induced Chemical Leukoderma Successfully Treated with 308-Nanometer Excimer Laser
Abstract
Introduction: Chemical leukoderma (CL) is an acquired depigmenting disorder caused by repeated exposure to chemical compounds. Thymol is a phenol derivative used as a preservative or antiseptic in many commercially available products. Here, we present the second reported case of CL caused by a thymol-containing compound.
Case presentation: A 48-year-old woman presented with a 4-month history of depigmentation of the nail folds of all ten fingers. This occurred after 1 month of twice-daily application of a thymol-containing compound intended for the removal of gel nails. No improvement was noted after the product was discontinued. There was no family history of vitiligo or other autoimmune disorders. On physical exam, depigmentation of all ten proximal and lateral nail folds was seen, with accentuation on Wood's lamp exam. Partial re-pigmentation was achieved after 32 treatments with 308-nm excimer laser.
Discussion: A thorough history and physical exam are instrumental in differentiating CL from other causes of depigmentation. Avoidance of the offending agent is an essential part of management. It is important to note that many cosmetic products are not tightly regulated by the FDA. Excimer laser is an effective treatment for CL with a favorable side-effect profile.
Keywords: Chemical; Contact; Depigmentation; Laser; Leukoderma.
Copyright © 2020 by S. Karger AG, Basel.
Conflict of interest statement
The authors have no relevant disclosures.
Figures


Similar articles
-
Treatment of Laser Therapy-Induced Punctate Leukoderma Using a 308-nm Excimer Laser.Ann Dermatol. 2017 Oct;29(5):630-632. doi: 10.5021/ad.2017.29.5.630. Epub 2017 Aug 25. Ann Dermatol. 2017. PMID: 28966523 Free PMC article.
-
Clinical and epidemiological analysis in 149 cases of rhododendrol-induced leukoderma.J Dermatol. 2017 May;44(5):582-587. doi: 10.1111/1346-8138.13694. Epub 2016 Nov 24. J Dermatol. 2017. PMID: 27882588
-
Chemical Leukoderma Improved by Low-dose Steroid Pulse Therapy.Ann Dermatol. 2010 May;22(2):241-4. doi: 10.5021/ad.2010.22.2.241. Epub 2010 May 19. Ann Dermatol. 2010. PMID: 20548927 Free PMC article.
-
Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review.Lasers Med Sci. 2013 May;28(3):1035-41. doi: 10.1007/s10103-012-1185-1. Epub 2012 Aug 15. Lasers Med Sci. 2013. PMID: 22892613 Review.
-
Depigmentation therapies for normal skin in vitiligo universalis.J Eur Acad Dermatol Venereol. 2011 Jul;25(7):749-57. doi: 10.1111/j.1468-3083.2010.03876.x. Epub 2010 Nov 4. J Eur Acad Dermatol Venereol. 2011. PMID: 21054565 Review.
References
-
- Bonamonte D, Vestita M, Romita P, Filoni A, Foti C, Angelini G. Chemical leukoderma. Dermatitis. 2016;27((3)):90–9. - PubMed
-
- Saleem MD, Oussedik E, Schoch JJ, Berger AC, Picardo M. Acquired disorders with depigmentation: a systematic approach to vitiliginoid conditions. J Am Acad Dermatol. 2019;80((5)):1215–31.e6. - PubMed
-
- Kang HH, Rho HS, Hwang JS, Oh SG. Depigmenting activity and low cytotoxicity of alkoxy benzoates or alkoxy cinnamte in cultured melanocytes. Chem Pharm Bull. 2003;51((9)):1085–8. - PubMed
-
- Vine K, Meulener M, Shieh S, Silverberg NB. Vitiliginous lesions induced by amyl nitrite exposure. Cutis. 2013;91((3)):129–36. - PubMed
Publication types
LinkOut - more resources
Full Text Sources